In vivo animal stroke models: a rationale for rodent and non-human primate models.

Abstract

On average, every four minutes an individual dies from a stroke, accounting for 1 out of every 18 deaths in the United States. Approximately 795,000 Americans have a new or recurrent stroke each year, with just over 600,000 of these being first attack [1]. There have been multiple animal models of stroke demonstrating that novel therapeutics can help improve the clinical outcome. However, these results have failed to show the same outcomes when tested in human clinical trials. This review will discuss the current in vivo animal models of stroke, advantages and limitations, and the rationale for employing these animal models to satisfy translational gating items for examination of neuroprotective, as well as neurorestorative strategies in stroke patients. An emphasis in the present discussion of therapeutics development is given to stem cell therapy for stroke.

• Authors: Naoki Tajiri, Travis Dailey, Christopher Metcalf, Yusef I Mosley, Tsz Lau, Meaghan Staples, Harry van Loveren, Seung U Kim, Tetsumori Yamashima, Takao Yasuhara, Isao Date, Yuji Kaneko, Cesario V Borlongan
• Journal: Translational stroke research (Transl Stroke Res) Vol. 4 Issue 3 Pg. 308-21 (Jun 2013) ISSN: 1868-601X [Electronic] United States
• PMID: 23682299 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Review)

Chemical References

• Drug Combinations

Topics

• Aging (physiology)
• Animals
• Cell Transplantation (methods, trends)
• Diabetic Angiopathies (complications)
• Disease Models, Animal
• Drug Combinations
• Heart Arrest (complications)
• Hyperlipidemias (complications)
• Hypertension (complications)
• Primates
• Rodentia
• Stem Cell Transplantation (methods, trends)
• Stroke (etiology, physiopathology, therapy)